TechCrunch’s Devin Coldewey profiles ReviveMed, a biotech startup out of MIT that turns drug discovery into a big data problem. “ReviveMed’s approach is a fundamentally modern one that wouldn’t be possible just a few years ago, such is the scale of the data involved,” writes Coldeway.
Prof. Hugh Herr and his team in the Biomechatronics Group are developing prosthetics that “respond to neural commands with the flexibility and speed of regular limbs,” writes Eillie Anzilotti for Fast Company. In a process pioneered by the group, “doctors leave the tendons and nerve endings intact so they can continue to feed sensations down past where the human leg ends,” Anzilotti says.
James Gallagher of BBC News speaks with several experts about the microbiome and how diversity in gut bacteria is essential to health. “One thing that we're learning is, based on the microbiome, different people may need to consume different diets in order to get the same effect,” says Prof. Eric Alm.
Research published in Science Translational Medicine suggests that inflammation caused by tumor removal surgery may actually encourage the emergence of new tumors. Daniel Uria for UPI reports that the study, led by Prof. Robert Weinberg, identified “perioperative anti-inflammatory treatment” as a way to substantially reduce the likelihood of “early metastatic recurrence in breast cancer patients.”
New research from MIT and the Whitehead Institute suggests that “the body’s own mechanism for healing” may cause cancerous cells to spread after breast cancer-related surgeries, reports Karen Weintraub for WBUR CommonHealth. “The post-surgical wound-healing response somehow releases…cells that have already spread to distant sites in the body,” explains Prof. Robert Weinberg, “releasing them from the constraints that have previously prevented them from growing actively.”
Synlogic, founded by Prof. Jim Collins and Associate Prof. Tim Lu, is programming probiotic bacteria to treat certain genetic or acquired metabolic disease, reports Robin Seaton Jefferson for Forbes. One product is used for people whose bodies can’t maintain a healthy level of ammonia and “has been specifically engineered to convert the excess ammonia to a harmless metabolite,” explains Seaton Jefferson.
Research led by Prof. Amy Finkelstein found that just 4% of “bankruptcy filings by non-elderly adults” were associated with medical expenses. “Medical bankruptcy…wasn’t nearly as common as anticipated,” writes Alex Kingsbury for The Boston Globe. “Public policy aimed at fighting it might not have the anticipated results, either.”
A study co-authored by researchers at MIT finds that hospitalizations only cause about 4 percent of bankruptcies among nonelderly adults in the U.S., reports Tom Murphy of the Associated Press. Researchers gathered data from “more than a half million adults under 65 in California who had a hospitalization between 2003 and 2007 that wasn't tied to childbirth.”
Researchers have developed a microfluidic platform called “physiome on a chip”, which allows them to determine how certain drugs will affect up to 10 different organs. “Because the animal and human immune systems are different, [drug] testing is difficult in non-human trials,” writes Allen Cone for UPI, “but [this] system could help with that.”
Prof. Linda Griffith has created a “complex platform where researchers can put up to 10 organ tissues in separate compartments, regulating the flow of substances and medications between them in real time,” to determine how each organ will react, writes Devin Coldewey for TechCrunch. The scale of this model “represents a huge jump in the capabilities of this kind of system.”
Prof. Linda Griffith has developed ten miniature models of human organs “to create the closest we’ve come yet to a human-on-a-chip,” writes Jessica Hamzelou for New Scientist. “This is still only a minimal representation of a human,” said Griffith, but this kind of system could eventually eliminate the need for animal testing.
MIT researchers have developed a new capsule that allows HIV medication to be delivered over the course of a week, and could allow patients to forgo daily pills, reports Ed Cara for Gizmodo. Researchers also found that using this method for the pre-exposure pill, “would manifest in approximately a 20 per cent increase in efficacy” for weekly dosage compared to the daily regimen.
MIT researchers have developed a new slow-release capsule that could free HIV patients from having to take a daily dose of medication, according to the BBC. “Changing a medication so it only needs to be taken once a week rather than once a day should be more convenient and improve compliance,” explains research affiliate Giovanni Traverso.
UPI reporter Alan Mozes writes that MIT researchers have developed a new capsule that could be used to deliver a week’s worth of HIV medications in a single dose. “The new pill sits in the stomach for a full week, as each of seven pill compartments opens up, one-by-one, to deliver a 24-hour dose of three HAART drugs,” Mozes explains.
CBS Boston spotlights how Portal Instruments, an MIT startup, is bringing a needle-free injector to the market, which could change the way people take medicine. The device, “fires a pressurized spray to penetrate the skin, instead of piercing the skin with traditional needles.”